Desirable Properties of Radiopharmaceuticals for Sentinel Node Mapping in Patients With Breast Cancer Given the Paradigm Shift in Patient Management.

Over the past 2 decades, lymphoscintigraphy and sentinel node biopsy have become widely accepted and are used by surgeons to stage many solid cancers, especially breast cancer. However, despite growing experience, there are a number of unresolved issues. In addition, the impact of a new radiopharmaceutical remains to be determined. The present article addresses some of these issues (either unresolved, recurrent, or newly emerged), with a focus on the properties of radiopharmaceuticals used for sentinel node mapping in breast cancer.